Dimebon disappointment by Jones, Roy W
One swallow does not make a summer, and one positive 
clinical trial does not make an Alzheimer’s drug. Th  is  was 
the Alzheimer Research Forum’s response in March 2010 
[1] to the news release by Pﬁ  zer Inc. and Medivation Inc. 
of the much-awaited data from the phase 3 
CONNECTION study with dimebon (latrepirdine) [2]. 
Unfortunately, the trial met neither its co-primary 
(cognition and global function) nor its secondary eﬃ   cacy 
endpoints. Th   is disappointing news increased scepticism 
about the unusually positive results of the original phase 
2 trial carried out in Russia and published in the Lancet
in 2008 [3].
Dimebon is orally available and was previously 
approved in Russia as a nonselective antihistamine but 
withdrawn from the market with the development of 
more selective compounds [4]. More recent papers 
described weak inhibition of butyrylcholinesterase, 
acetyl cholinesterase,  the  N-methyl-d-aspartate receptor 
signal  l  ing pathway and the mitochondrial permeability 
transi  tion pore opening [4-7]. Together with the 
demonstration of neuroprotective eﬀ  ects in Alzheimer’s 
disease (AD) and Huntington’s disease models, these 
obser  vations supported the potential of dimebon as a 
treatment for AD – although the plausibility of dimebon’s 
mechanism of action has been queried [8].
In the phase 2 placebo-controlled study in mild-to-
moderate AD funded by Medivation Inc., 155 patients 
(85% of those enrolled) completed the study [3]. Dimebon 
(20 mg three times daily) was safe and well tolerated, and 
signiﬁ  cantly improved the clinical course of patients [3]; 
the mean change from baseline scores signiﬁ  cantly 
favoured the drug for all ﬁ   ve outcome measures: two 
measures of cognition (Mini-mental State Examination, 
and Alzheimer’s Disease Assessment Scale cognitive 
subscale), one measure of activities of daily living 
(Alzheimer’s Disease Cooperative Study activities of daily 
living), one measure of behaviour (Neuropsychiatric 
Inventory) and a global rating scale (Clinician’s Interview-
based Impression of Change plus Caregiver Input). Th  e 
drug–placebo diﬀ  erences were not driven by worsening 
in the placebo group and there was a widening drug–
placebo diﬀ  erence over the 26-week study. A 26-week 
blinded extension phase was included, and the 
Alzheimer’s Disease Assess  ment Scale cognitive subscale 
and the Alzheimer’s Disease Cooperative Study activities 
of daily living diﬀ  er  ences increased further from 26 to 52 
weeks [3]. Th  e authors commented that the increasing 
beneﬁ  t was especially important because ‘at present no 
approved therapies for mild-to-moderate AD have shown 
increasing improvement over 12 months’ [3]; further-
more, other treatments had not shown such consistent 
results across several standardised measures within one 
study.
Not surprisingly, these results created a great deal of 
excitement and expectation – although the authors 
cautioned that this was a single-country trial of one dose 
of dimebon, and that a larger multinational study was 
needed to conﬁ  rm the ﬁ  ndings.
Th  e CONNECTION study was the larger study co-
sponsored by Pﬁ  zer Inc. (who had now entered into a 
global collaboration with Medivation Inc. for the 
develop  ment of dimebon) involving 598 patients with 
mild-to-moderate AD at 63 sites in North America, 
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to one of three treatment groups, receiving either 
dimebon 20 mg three times daily (as for the original 
study) or 5 mg three times daily (to help deﬁ  ne  the 
eﬀ   ective dose range [2]) or placebo. Th  e co-primary 
endpoints were cognition (Alzheimer’s Disease 
Assessment Scale cognitive subscale) and global function 
(Clinician’s Interview-based Impression of Change plus 
Caregiver Input). After 6 months of treatment, there 
were no signiﬁ  cant diﬀ  erences between any of the three 
groups. Secondary endpoints were also negative, 
including the Mini-mental State Examination – in which 
the placebo group actually performed numerically better, 
although the diﬀ  erences were nonsigniﬁ  cant.
Dimebon was well tolerated in the CONNECTION 
study and also in a separate phase 3 safety and tolerability 
study, which conﬁ  rmed dimebon’s good tolerability when 
dosed alone or in combination with other approved AD 
medications [2].
So why are the study results so diﬀ  erent? Th   e authors of 
the phase 2 study comment that the patients were younger 
(mean age 68.1 years) than those usually recruited to 
Alzheimer’s studies worldwide, and in the phase 3 trial the 
mean age was 74.4 years. In the Russian study, the mean 
baseline Mini-mental State Examination score was 18.7 
compared with a mean score of 17.7 on entry to the phase 
3 study. Th  e  beneﬁ  ts of dimebon in the phase 2 study were 
not driven by worsening in the placebo group, but reﬂ  ected 
an actual improvement on dimebon as well as a decline on 
placebo. In the phase 3 trial, however, the patients in the 
trial did not deteriorate signiﬁ  cantly in either the drug-
treated group or the placebo group, which makes 
interpretation of the study more diﬃ   cult. Patients in one 
country (Russia) might well be diﬀ  erent from those taking 
part in a multinational study (in the phase 3 trial, more 
than 40% of the patients were from the USA).
Most comments seem to have questioned the validity 
of the Russian data, and there are potential concerns 
about this validity – as there have been about Russian 
data on an anticancer drug (NOV-002), which also 
showed dramatically positive results not supported by 
the subsequent phase 3 study [8]. Th  e  dimebon 
formulation used in Russia appears diﬀ  erent from that of 
the multinational study. Th  e original medication has a 
bitter taste and a numbing eﬀ  ect on the tongue [8], which 
could lead to unblinding, whereas in the later study the 
tablet was ﬁ  lm-coated. Th   ere have been other comments 
about whether the same compound was used in both 
studies because of the diﬀ  erent side-eﬀ  ect proﬁ  les [1]. 
Dry mouth was the commonest side eﬀ  ect seen in the 
Russian study (14% of patients at 26 weeks and 18% at 52 
weeks in comparison with just 1% on placebo) [3], but 
somnolence and head  ache were the commonest side 
eﬀ  ects in the multinational study (and the incidence was 
more balanced between drug-treated and placebo 
groups: somnolence, 11% active versus 10.1% placebo; 
headache, 9.5% versus 5.6%; and dry mouth, 8.5% versus 
6.6%) [2].
Equally questionable is whether the multinational study 
recruited typical patients, especially when more than 40% 
were recruited from the USA. Th  e study did not allow 
recruitment of patients who were receiving or had received 
within 90  days either cholinesterase inhibitors or 
memantine. Th   e normal treatment for most patients with 
AD would be a cholinesterase inhibitor or memantine or 
combi  na  tion therapy, and it may therefore be that patients 
who do not receive this are atypical yet they would be the 
patients recruited to the study. Th   ere are clearly a number 
of other diﬀ  erences between the Russian phase 2 study and 
the multinational phase 3 study.
Th  e results of the phase 3 study have led to further 
negative comments about the underlying rationale for the 
use of dimebon in AD and the limited preclinical data 
that are available. Dr Samuel Gandy commented that ‘this 
was a drug with no plausible mechanism that emerged 
from an incomprehensible series of screens’, whilst Dr 
Lon Schneider commented on the limited pharmaco-
kinetic data available [8].
Th  e negative phase 3 study has already led to a 
reduction in the dimebon clinical trial programme, with 
a number of studies having stopped (for example, see 
study NCT01066546 on clinicaltrials.gov). One 12-month 
study (NCT00829374) is continuing, however, comparing 
two doses of dimebon with placebo and recruiting 1,050 
patients with mild-to-moderate AD who are stable on 
donepezil. Th  ese patients are likely to be more typical 
than those in the previous phase 3 monotherapy study 
and are being recruited in the USA, Europe, Australia 
and New Zealand; it is important that we wait for these 
results. If the results of this study are also negative, then 
yet another potential Alzheimer’s therapy will have fallen 
at the phase 3 hurdle – although in this case after a strong 
phase 2 signal that perhaps was too good to be true. Th  is 
will be disappointing and would conﬁ  rm how far we may 
still have to go before we achieve real advances in therapy 
for patients with AD.
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